touchONCOLOGY joins Dr Omid Hamid (Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, Los Angeles, CA, USA) at ASCO 2021 to discuss nemvaleukin alfa and the ARTISTRY-2 trial.
The abstract ‘Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2’ (NCT03861793) (abstract number 2552) was presented at the 2021 ASCO Annual Meeting.
1. Could you tell us a little about nemvaleukin alfa and its mechanism of action? (0:15-01:32)
2. What are the aims of the ARTISTRY clinical trial program, and what have we learned to date? (01:32-02:49)
3. Which tumour types were included in ARTISTRY-2? (02:49-04:09)
4. What were the efficacy and safety findings of ARTISTRY-2? (04:09-05:15)
5. What will be the next steps in the ARTISTRY clinical trial program? (05:15-07:26)
Disclosures: Consulting/Advisory Boards: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, Seattle, Genetics, Tempus, Zelluna. Speaker Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron. Contracted Research (For Institution): Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Pfizer, Sanofi/Regeneron, Seattle Genetics, Torque, Zelluna.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.
Filmed in coverage of the 2021 ASCO Annual Meeting.
Share this Video
Related Videos In Immunotherapy
Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment. Questions Could you give us a brief overview of the current approval status of CAR-T […]
Michael Atkins: Safe and Effective Use of Immune Checkpoint Inhibitors in Patients with Cancer
Dr Michael Atkins (MedStar Georgetown University Hospital, Washington, DC, USA) shares three areas for development to help improve the safe and effective use of immune checkpoint inhibitors. 1. Having a rational approach to stopping therapy (00:50-02:20) 2. An improved understanding of toxicity and response (02:20-04:25) 3. The role of combining and sequencing immunotherapy with standard […]
Lyudmila A Bazhenova, WCLC 2021: Challenges of Widespread Immunotherapy
touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer. Questions 1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51) 2. What are […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!